Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for inflammatory and immune-mediated diseases. The company operates within the biopharmaceutical and immunology sectors, with a primary emphasis on novel biologic drugs designed to modulate immune system pathways. Its core revenue model is currently research- and development-driven, with no commercialized products as of the most recent public filings, and funding primarily derived from equity financing, collaborations, and prior licensing agreements.
AnaptysBio’s strategic positioning centers on its proprietary antibody discovery and optimization technologies, which are designed to generate highly selective therapeutic antibodies. The company was founded in 2005 and initially focused on antibody engineering platforms before evolving into a product-driven biotechnology company with internally developed clinical assets. Over time, AnaptysBio transitioned from a platform-licensing model toward advancing wholly owned drug candidates through clinical development.
Business Operations
The company’s operations are organized around the discovery and clinical development of antibody therapeutics targeting specific immune pathways. Its primary business activities include preclinical research, clinical trials, regulatory strategy, and manufacturing oversight through third-party contractors. Key product candidates include therapeutic antibodies targeting immune receptors and cytokines implicated in inflammatory diseases, which represent the company’s principal value drivers.
AnaptysBio conducts the majority of its research and development activities internally in the United States while relying on external contract research organizations for clinical trials and manufacturing. The company controls proprietary antibody engineering technologies and maintains full or shared rights to its clinical programs. Historically, it has entered into collaboration and licensing arrangements with larger pharmaceutical companies, although its current strategy emphasizes retaining greater ownership of its development programs.
Strategic Position & Investments
AnaptysBio’s strategic direction prioritizes advancing late-stage clinical candidates for immune-mediated diseases with high unmet medical need. Growth initiatives focus on progressing lead programs through Phase 2 and Phase 3 clinical trials, optimizing clinical trial design, and selectively pursuing partnerships that enhance development or commercialization capabilities without diluting long-term asset value.
The company has made targeted investments in expanding its clinical pipeline rather than pursuing large-scale acquisitions. Its portfolio consists primarily of internally developed antibody programs rather than externally acquired assets. AnaptysBio is also involved in emerging immunology research areas, including targeted immune receptor modulation, which positions it within a competitive but rapidly evolving therapeutic landscape.
Geographic Footprint
AnaptysBio is headquartered in the United States, with its principal offices located in California. Its operational footprint is primarily domestic, with research and corporate functions centralized at its headquarters. Clinical development activities, however, are international in scope due to the global nature of clinical trials.
The company conducts or supports clinical studies across North America, Europe, and other international regions through partnerships with global clinical research organizations. While it does not maintain extensive foreign subsidiaries, its clinical and regulatory activities give it an operational presence across multiple continents.
Leadership & Governance
AnaptysBio was founded by scientists with expertise in antibody engineering and immunology, shaping a leadership culture focused on scientific rigor and disciplined clinical execution. The company is governed by a board of directors with experience in biotechnology, pharmaceuticals, and capital markets, supporting its strategy as a publicly traded clinical-stage company.
Key members of the executive leadership team include:
- Daniel M. Faga – President and Chief Executive Officer
- James N. Topper, M.D., Ph.D. – Chief Scientific Officer
- Sheela Damle, M.D. – Chief Medical Officer
- Brandon Chan – Chief Financial Officer
- Teresa Bitetti, Ph.D. – Board Chair
The leadership team emphasizes a strategy of advancing differentiated immunology assets through disciplined clinical development while maintaining financial flexibility and strong governance practices consistent with U.S. public company standards.